NeuroZone
Neuro-Zone is a Milan-based preclinical CRO (founded 2007) providing custom drug discovery services to biotech and pharma companies, using proprietary cell-based platforms, disease models, and microfluidic organ-on-a-chip technology for inflammation and age-related pathologies.
- Company typePrivate
- Founded2007
- HeadquartersMilan, Italy
- Headcount1–10
- GTM typeB2B
- OfferingServices
What NeuroZone does
Neuro-Zone S.r.l. is a privately-held preclinical contract research organization (CRO) founded in 2007 in Milan, Italy, operating from the MIND - Milano Innovation District within the Bio4Dreams ecosystem. The company supports biotech and pharmaceutical clients across all stages of preclinical drug discovery, from chemical library screening through candidate compound validation, with a stated focus on inflammation and age-related pathologies. Customers include both biotech companies (Axxam, Cerespir, Chronos Therapeutics, CILCare, Delix Therapeutics) and pharmaceutical companies (Saniona, Servier), alongside academic and research institute partners (IAR-Aosta, Szentagothai Research Center, Tampere University).
The company's offering is structured around three service lines — Multiparametric Assays, Pathology Specific Models, and Cell Platforms — underpinned by proprietary platforms including Cell Phenotyping (BD FACSARIA III flow cytometry), OTOTOX (ototoxicity screening with a licensed HEI-OC1 cell line), MITOS (mitochondrial function assays), ELECTRA (patch-clamp electrophysiology), MicroTISSUE (microfluidic tissue models), and a human BBB in vitro model developed under the ERC-PoC-funded DIANA project with Politecnico di Milano. Disease models span autoimmune disorders, brain diseases (Alzheimer, Parkinson, ALS, brain ischemia, Batten), cancer, sensory organ pathology, and inflammatory conditions.
NeuroZone generates revenue through bespoke contract research projects billed per scope, with quote-based pricing and multi-year contracts. The company supplements commercial service revenue with non-dilutive funding from European and regional grants (FP7, ERC-PoC, Regione Lombardia, Regione Valle d'Aosta). It operates with a 1–10 person leadership team covering scientific, financial, legal, and grant management functions, and distributes services via direct B2B sales, ecosystem-mediated referrals, and grant-funded consortium collaborations. Its go-to-market is sales-led, targeted at enterprise biotech and pharma buyers, with event-driven visibility through collaborative research projects.
NeuroZone firmographics
Firmographics- Name
- NeuroZone
- Legal name
- Neuro-Zone S.r.l.
- Website
- https://neuro-zone.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Neuro-Zone is a Milan-based preclinical CRO (founded 2007) providing custom drug discovery services to biotech and pharma companies, using proprietary cell-based platforms, disease models, and microfluidic organ-on-a-chip technology for inflammation and age-related pathologies.
- Ownership category
- akta.pro rank
NeuroZone industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where NeuroZone is headquartered
LocationHeadquarters
- HQ city
- Milan
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
NeuroZone business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Contract Research Services: Tailored contract research projects for preclinical drug discovery, supporting biotech and pharma companies from screening of chemical libraries to validation of candidate compounds. Revenue generated through custom service agreements and project-based contracts.
- Custom Service Solutions: Customized multiparametric assays, pathology-specific models, and cell platform services billed per project based on scope and complexity.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom service quotes based on project scope |
Go-to-market motion3 records
Distribution channels1 record
Marketing channels4 records
NeuroZone product offering
Product offeringCore offering
NeuroZone is a preclinical contract research organization (CRO) providing functional drug discovery services to biotech and pharma companies. The company offers a portfolio of in vitro disease models, multiparametric cell-based assays, and specialized cell platforms (Cell Phenotyping via flow cytometry, OTOTOX for ototoxicity, MITOS for mitochondrial function, ELECTRA for electrophysiology, and a MicroTISSUE microfluidic platform) to support screening, hit-to-lead, mode-of-action studies, and candidate validation. Services are delivered through tailored contract research projects and collaborative research partnerships across therapeutic areas including CNS, cancer, autoimmune, otic, and inflammatory diseases.
Product overview
Neuro-Zone is a functional preclinical contract research organization (CRO) serving biotech and pharma companies across all stages of preclinical drug discovery, from chemical library screening to candidate compound validation. The company operates a unified platform-plus-services architecture consisting of three main service lines — Multiparametric Assays, Pathology Specific Models, and Cell Platforms — underpinned by four specialized technology platforms (Cell Phenotyping via BD FACSARIA III flow cytometry, Ototox for ototoxicity screening, Mitos for mitochondrial analysis, and Electra for electrophysiology), plus a MicroTISSUE microfluidic platform. Together these offerings enable multiparametric readouts across disease areas including brain diseases, cancer, autoimmune disorders, and sensory disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- Multiparametric Assays
Quantifiable outcome
- Increases confidence of cell-based data to efficiently advance preclinical programs
- +1 more outcomes
Companies that use NeuroZone
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
NeuroZone technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
NeuroZone partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered major, core and minor.
- S.E.R.E.N.A. ConsortiummajorS.E.R.E.N.A. project - Soluzioni Evolute per la Riabilitazione e l'Engagement di pazienti in Network Assistiti con AI. Project builds integrated digital ecosystem for remote and intelligent management of frailty using sensors, wearable devices, AI and digital platforms. Consortium includes Azcom Technology (leader), Eletech, ROLD, and Valos. Funded by Regione Lombardia 'Bando Tecnologie Strategiche'.
- SaluteDerm ConsortiummajorNeuroZone serves as main coordinator of SaluteDerm project with partners IAR (Institute of Applied Research), LINKS Foundation, and Thallosjet Srl. Project develops advanced solutions for precise diagnosis and targeted treatment of skin lesions, funded by Regione Valle d'Aosta 'Aggregazioni R&S Salute' call.
- BiomimXcoreCommercial partnership where NeuroZone leverages its sales network to support BiomimX's business development by identifying and introducing potential clients and conducting marketing activities, specifically for the uKnee model service line. This enhances NeuroZone's technological offering in preclinical models for inflammatory musculoskeletal disorders.
- Politecnico di MilanocoreCollaboration on DIANA project - Organ-on-a-chip Drug screenIng device to tArget braiN disease, an ERC-2019-PoC Grant. Project focuses on demonstrating technical and commercial feasibility of integrated BBB-brain model in vitro based on patented organ-on-a-chip technology.
- Neon Project ConsortiummajorConsortium led by Dompé Farmaceutici to create innovative platform for drug development targeting CNS and oncological diseases. Partners include Vita-Salute San Raffaele University, University of Milan, Politecnico di Milano, European Institute of Oncology, CNR Institute of Neurosciences, Italian Institute of Technology, and Proxentia.
- Bio4DreamscoreNeuroZone is part of Bio4Dreams ecosystem, located within their headquarters at MIND - Milano Innovation District. Provides access to state-of-the-art facilities within SharedLabs and integration into dynamic life sciences ecosystem.
- CILCarecoreLicensed otic cell line (HEI-OC1) from CILCare for OTOTOX platform. Cell line faithfully reproduces inner ear and is susceptible to antibiotics and chemotherapeutics for ototoxicity screening.
- AxxamminorBiotechnology company partner and client of NeuroZone services.
- CerespirminorBiotechnology company partner and client of NeuroZone services.
- Chronos TherapeuticsminorBiotechnology company partner and client of NeuroZone services.
- CilcarecoreBiotechnology company providing licensed otic cell line for OTOTOX platform and client of NeuroZone services.
- Delix TherapeuticsminorBiotechnology company partner and client of NeuroZone services.
- IAR-AostamajorInstitute of Applied Research partner in SaluteDerm project for skin lesion diagnosis and treatment solutions.
- SanionaminorPharmaceutical company partner and client of NeuroZone services.
- ServierminorPharmaceutical company partner and client of NeuroZone services.
- Szentagothai Research CenterminorResearch institution partner and client of NeuroZone services.
- Tampere UniversityminorUniversity partner and client of NeuroZone services.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
NeuroZone competitors and assessment
Company assessmentBroad incumbents
- Inotiv: US-based preclinical CRO and research models provider offering discovery, safety assessment, and research models services. Broad incumbent in preclinical contract research with overlapping in vivo and in vitro capabilities relevant to NeuroZone's offerings.
- Eurofins Discovery: Global discovery and preclinical CRO within the Eurofins network offering in vitro pharmacology, ADME, and safety services. Overlaps with NeuroZone's multiparametric assay and in vitro disease-model offerings at much larger scale.
- Charles River Laboratories: Major global CRO offering preclinical research, discovery, safety assessment, and manufacturing services. Competes for the same biotech and pharma preclinical outsourcing budgets as NeuroZone, but at much greater scale and with broader service breadth.
- Evotec: Global full-service drug discovery and development CRO offering preclinical through clinical services. Comparable as a broad incumbent in preclinical CRO services, though operating at vastly larger scale and across the full discovery-to-clinic value chain versus NeuroZone's specialized preclinical focus.
- Pharmaron: China/UK-headquartered fully integrated CRO offering preclinical discovery through clinical development. Competes for outsourced preclinical programs from biotech and pharma, though at significantly larger scale than NeuroZone.
Emerging players
- Ncardia: Belgium-based biotech specializing in iPSC-derived cardiac and neural disease models for drug discovery. Emerging peer in the in vitro disease-model space, with overlapping neuroscience and cardiac safety applications comparable to NeuroZone's pathology-specific models.
- Axol Bioscience: UK-based supplier of iPSC-derived neural and cardiac cell models used in neuroscience and drug discovery research. Emerging player in the neural cell-based assay market with overlapping applications to NeuroZone's CNS and electrophysiology platforms.
Direct peers
- Axxam: Milan-based preclinical CRO providing ion channel drug discovery, screening, and assay development services. Directly comparable as an Italian boutique preclinical CRO with overlapping customer base and screening/electrophysiology capabilities similar to NeuroZone's ELECTRA platform.
- CILCare: French preclinical CRO specializing in hearing disorders and ototoxicity assessment. Direct peer in the ototoxicity screening niche, and an existing technology partner of NeuroZone via the licensed HEI-OC1 otic cell line powering the OTOTOX platform.
- Sygnature Discovery: UK-based integrated drug discovery CRO with strong in vitro pharmacology and disease-model capabilities. Comparable mid-sized preclinical CRO with similar client base (biotech and pharma) and custom assay/contract research service model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks3 records
Key highlights7 records
Customer concentration
NeuroZone social profiles
Digital presenceNeuroZone financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroZone leadership team
Management profileNumber of profiles
Profiles10 records
NeuroZone funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroZone M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroZone
What does NeuroZone do?
NeuroZone is a preclinical contract research organization (CRO) providing functional drug discovery services to biotech and pharma companies. The company offers a portfolio of in vitro disease models, multiparametric cell-based assays, and specialized cell platforms (Cell Phenotyping via flow cytometry, OTOTOX for ototoxicity, MITOS for mitochondrial function, ELECTRA for electrophysiology, and a MicroTISSUE microfluidic platform) to support screening, hit-to-lead, mode-of-action studies, and candidate validation. Services are delivered through tailored contract research projects and collaborative research partnerships across therapeutic areas including CNS, cancer, autoimmune, otic, and inflammatory diseases.
Is NeuroZone a public or private company?
NeuroZone is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeuroZone founded?
NeuroZone was founded in 2007. It employs 1 to 10 people.
Where is NeuroZone based?
NeuroZone is headquartered in Milan, Italy, in the Europe region.
How does NeuroZone make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are custom Service Solutions.
Who are NeuroZone's main competitors?
Broad incumbents on record are Inotiv, Eurofins Discovery, Charles River Laboratories, Evotec and Pharmaron. Emerging players are Ncardia and Axol Bioscience. Direct peers are Axxam, CILCare and Sygnature Discovery.
Does NeuroZone have an API?
No public API is recorded for NeuroZone.
What industry is NeuroZone in?
NeuroZone's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.